Morgan Stanley Xenetic Biosciences, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.31 - $0.73 $935 - $2,202	-3,017 Reduced 50.54%	2,952 $1,000
Q4 2022 Feb 14, 2023	BUY	$0.27 - $5.75 $4 - $97	17 Added 0.29%	5,969 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $5.57 $3,954 - $37,330	-6,702 Reduced 52.96%	5,952 $4,000
Q2 2022 Oct 27, 2022	SELL	$0.6 - $1.14 $6 - $12	-11 Reduced 0.09%	12,654 $10,000
Q2 2022 Aug 15, 2022	SELL	$0.6 - $1.14 $6 - $12	-11 Reduced 0.09%	12,654 $10,000
Q1 2022 Oct 27, 2022	BUY	$0.88 - $1.37 $9 - $15	11 Added 0.09%	12,665 $13,000
Q1 2022 May 13, 2022	BUY	$0.88 - $1.37 $9 - $15	11 Added 0.09%	12,665 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.08 $9,495 - $15,552	7,477 Added 144.43%	12,654 $16,000
Q3 2021 Nov 15, 2021	BUY	$1.73 - $5.3 $8,956 - $27,438	5,177 New	5,177 $11,000

Ticker XBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,166,600
Market Cap $59.6M
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.